EDDING GENOR (06998) subsidiary enters into agreement with Taizhou Ectopia Jing'ang
EDDING GENOR (06998) announced that on November 17, 2026, Ectopia Pharma (Zhuhai), an indirectly wholly-owned subsidiary of the Company, entered into an agreement with Taizhou Ectopia Jing'ang, pursuant to which Ectopia Pharma (Zhuhai) engaged Taizhou Ectopia Jing'ang to conduct process technology transfer, provide regulatory filing support, and carry out commercial production at Taizhou Ectopia Jing'ang's facilities for two products: (i) Rujianing; and (ii) Wenkeda.
EDDING GENOR (06998) announces that on November 17, 2026, Ectopia Pharma (Zhuhai), an indirectly wholly-owned subsidiary of the Company, entered into an agreement with Taizhou Ectopia Jing'ang, pursuant to which Ectopia Pharma (Zhuhai) has engaged Taizhou Ectopia Jing'ang to conduct process technology transfer, provide regulatory filing support and carry out commercial manufacturing at Taizhou Ectopia Jing'ang's facilities in respect of two products: (i) Rujianing; and (ii) Wenkeda.
Pursuant to the agreement, Ectopia Pharma (Zhuhai) will also provide the equipment required for commercial manufacturing of the products, and Taizhou Ectopia Jing'ang will purchase such equipment by offsetting against product procurement payments at a lower double-digit percentage of the tax-inclusive total procurement price payable by Ectopia Pharma (Zhuhai) per unit of commercial product, until the total purchase price of such equipment has been fully offset.
The Board believes that entering into the agreement is in line with the Group's business needs to advance localized technology transfer, registration and commercial manufacturing of the relevant products, and to establish a stable and controllable domestic production and supply system. The technology transfer and commercialization arrangements under the agreement are commercially complementary and together constitute the Group's overall cooperation framework for allocating dedicated capacity for the relevant products, advancing technology transfer and ensuring continuous supply. The principal reasons for and expected benefits of the transactions under the agreement are as follows:
1. Enhancing supply security through dedicated capacity matched to product demand characteristics. The Group's existing production facilities currently do not have the conditions for co-line production of the products, and therefore a qualified third-party contractor must be engaged to undertake commercial manufacturing of the products. In terms of demand characteristics, taking into account patient numbers, treatment cycles and batch size requirements, Wenkeda requires relatively few production batches per year; while Rujianing is in a phase of rapid growth, making market demand forecasting more challenging. These characteristics require the contractor to maintain production line availability and scheduling priority despite the low number of production batches, while retaining the flexibility to rapidly scale up production and delivery when demand increases. Through the equipment deployment, contractor facility modification and commercial manufacturing arrangements under the agreement, dedicated production lines will be established for the products, with provisions on capacity reservation, procurement forecasts, contingency planning and supply security. These complementary arrangements enable capacity to match the respective demand characteristics of the two products, reduce the risk of capacity being occupied by other customers' orders and additional costs arising from order adjustments, improve the predictability of supply planning, and provide security for continuous commercial supply of the products.
2. Strengthening quality management and compliance risk control. The products are both oral solid dosage forms, involving process validation, cleaning validation, co-line production control and quality release. Taizhou Ectopia Jing'ang has experience in the development, registration and commercial manufacturing of relevant dosage forms, holds complete licenses and qualifications, and has a well-established quality management system. Dedicated production lines can provide more targeted arrangements in respect of production, hygiene and quality control, thereby reducing the quality management complexity arising from the risks of cross-contamination and mix-ups involved in multi-product co-line production.
3. Improving technology transfer, production and supply chain coordination. Engaging a single entrusted party within the agreed framework to undertake technology transfer, validation, registration support and commercial manufacturing, together with dedicated equipment and production lines, can reduce coordination costs, documentation interface issues and information transmission risks.
4. Supporting project implementation through equipment buy-back. The arrangement is intended to establish dedicated production lines for the products and is in line with prevailing practices in the pharmaceutical CDMO/contract manufacturing industry. The equipment buy-back arrangement links the recovery of the total equipment purchase price to actual production and sales volumes, ensuring that the offset progress is commensurate with the useful life of the equipment. Before the total equipment purchase price is fully offset, the Group retains ownership of the relevant equipment assets, providing an asset recovery pathway and reducing the risks of equipment idleness and impairment. The arrangement helps consolidate long-term cooperation between the contracting parties and safeguards the continuity and stability of production supply.
5. Protecting core technology and intellectual property. Taizhou Ectopia Jing'ang and the Group have established a long-term cooperative foundation. The dedicated production line arrangement, combined with relatively fixed production, quality and technical personnel, helps narrow the scope of access to and circulation of technical information. The agreement also sets out confidentiality obligations, restrictions on the use and custody of technical information, personnel management, liability for breach and audit rights.
6. Comprehensive evaluation criteria. The Group conducted a comprehensive evaluation of multiple candidate CDMO institutions, covering capabilities, compliance, supply security, co-line production risks, technology transfer and commercialization quotations. Other candidate CDMO institutions generally rely on shared production lines serving multiple customers, whereas Taizhou Ectopia Jing'ang proposed to establish dedicated production lines exclusively for the products, offering structural advantages in terms of capacity security, supply safety and reduced cross-contamination risks.
7. Verifiable risk allocation and pricing fairness safeguards. The Group will review the relevant pricing with reference to cost composition, procurement volume, comparable market data or third-party information (as applicable) and the results of independent arm's-length negotiations, and retains audit rights over major cost components and relevant financial records.
Related Articles

YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.
YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.






